ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 105 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,581 | -89.5% | 1,026 | -85.2% | 0.00% | -85.7% |
| Q2 2023 | $195,213 | +542158.3% | 6,920 | +230.9% | 0.01% | +600.0% |
| Q1 2023 | $36 | -29.4% | 2,091 | -18.9% | 0.00% | -50.0% |
| Q4 2022 | $51 | -100.0% | 2,578 | -57.2% | 0.00% | 0.0% |
| Q3 2022 | $130,000 | -39.5% | 6,021 | -21.2% | 0.00% | -60.0% |
| Q2 2022 | $215,000 | +795.8% | 7,640 | +1374.9% | 0.01% | – |
| Q1 2022 | $24,000 | -92.7% | 518 | -86.9% | 0.00% | -100.0% |
| Q4 2021 | $331,000 | +89.1% | 3,942 | +50.6% | 0.01% | +50.0% |
| Q3 2021 | $175,000 | +6.7% | 2,617 | -15.1% | 0.00% | 0.0% |
| Q2 2021 | $164,000 | +160.3% | 3,084 | +113.6% | 0.00% | +300.0% |
| Q1 2021 | $63,000 | +70.3% | 1,444 | +101.1% | 0.00% | 0.0% |
| Q4 2020 | $37,000 | -87.7% | 718 | -92.2% | 0.00% | -66.7% |
| Q3 2020 | $302,000 | +1158.3% | 9,234 | +1710.6% | 0.00% | +200.0% |
| Q2 2020 | $24,000 | – | 510 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |